Latest news
27 January 2025
Touchlight Appoints Industry Leader Will Downie as Adviser to Support Strategic Growth in Synthetic DNA Platforms
London, UK – January 27, 2025 – Touchlight, a pioneering leader in synthetic DNA technology, is pleased to announce the appointment of Will Downie as a key adviser to support its mission in advancing genetic medicines. Downie’s extensive experience as an industry leader delivering strategic business growth across pharmaceutical services and product development positions him … Continued
16 January 2025
Ceva Animal Health and Touchlight sign an agreement to use Touchlight’s dbDNA technology in animal health
Ceva and Touchlight entered into an agreement and a long-term collaboration for the development and manufacture of new dbDNA vaccines and therapeutics across a broad range of animal health indications. Libourne and London, 16 January 2025 – Ceva Animal Health (Ceva), the 5th largest global animal health company, today announced to being granted rights … Continued
14 January 2025
Touchlight’s dbDNA™ manufacturing facility receives world-first GMP license from MHRA
Touchlight’s dbDNA technology is the first synthetic DNA technology to receive a GMP certificate globally Touchlight manufacturing Active Pharmaceutical Ingredient (API) on behalf of contracted clients Touchlight, an innovation-driven Contract Development and Manufacturing Organisation (CDMO), today announced that its facility in Hampton UK has received GMP certification. As a result, Touchlight becomes the first synthetic … Continued
21 August 2024
Touchlight to supply GMP dbDNA to support University of Nottingham’s clinical study for a next-generation vaccine for Zika virus
Touchlight, an innovation-driven contract development and manufacturing organization (CDMO) specializing in enzymatic DNA production, is proud to announce the clinical supply of its proprietary dbDNATM to the University of Nottingham for research and development of a next-generation DNA vaccine targeting the Zika virus. Scientists from the University of Nottingham are leading the development of a … Continued
23 July 2024
Touchlight and GSK sign license agreement for use of enzymatic dbDNA production technology for mRNA manufacturing
Agreement enables GSK access to enzymatic production technology for rapid GMP production of DNA template for mRNA vaccine manufacturing Hampton, UK, 23 July 2024 – Touchlight, an innovation-driven CDMO pioneering enzymatic DNA production to enable the genetic medicine revolution, today announced a license agreement with GSK, a global leader in biopharmaceutical innovation. This agreement grants … Continued
2 July 2024
Touchlight and LenioBio collaborate to accelerate development of protein therapeutics for pandemic response
Touchlight to participate in LenioBio’s recently announced grant from CEPI 02 July, HAMPTON, United Kingdon and DÜSSELDORF, Germany – LenioBio, a biotech company pioneering cell-free protein production, and Touchlight, the leader in enzymatic DNA production, are pleased to announce a supply agreement aimed at leveraging the revolutionary capabilities of Touchlight’s rapid enzymatic doggybone DNA (dbDNATM), … Continued
9 May 2024
Touchlight Genetics and the National Physical Laboratory (NPL) awarded grant to develop novel gene-length single-stranded genome editing template.
Touchlight Genetics, in partnership with the National Physical Laboratory (NPL) have secured funding from Innovate UK under their Innovative Technologies: Nucleic Acid Medicines Manufacture, Round 2 call. As the development of genome editing technologies continues to gather pace, Touchlight has developed a novel, circular, single-stranded genome editing template known as MegaBulb DNA (mbDNA™). Increasing clinical … Continued
26 April 2024
Touchlight awarded grant extension to further develop DNA-enabled Biobatteries with U.S. Office for Naval Research and UK Defence Science & Technology Laboratory
Touchlight, a biotechnology CDMO pioneering enzymatic DNA production has been awarded a second grant from the Office of Naval Research (ONR) and the Defence Science and Technology Laboratory (Dstl) to continue work with Professor Shelley Minteer’s research group, Missouri University of Science and Technology, to further propel the development of DNA-enabled biobatteries. Biobatteries use enzymes … Continued
4 April 2024
University of Liverpool to use Touchlight’s rapid enzymatic dbDNA in fully personalised neoantigen cancer vaccine clinical study
The UK’s Medical Research Council is funding a 10-patient Phase I study to deliver rapid personalised treatment for lung cancer patients. Hampton, UK – 3 April 2024 – Touchlight, a CDMO enabling the development of genetic medicines with its enzymatic doggybone DNA (dbDNA™) technology, today announced an agreement with University of Liverpool for the use of … Continued
28 March 2024
Touchlight awarded tender to supply enzymatic dbDNA to CPI’s RNA Centre of Excellence
Touchlight, an innovation-driven CDMO enabling the development of genetic medicines with its doggybone DNA (dbDNA™) technology and leaders in enzymatic DNA production, is delighted to announce that it has been awarded a tender to deliver enzymatic DNA as part of CPI’s tender process for the establishment of its RNA Centre of Excellence. CPI, a leading … Continued
21 November 2023
Touchlight’s enzymatic doggybone DNA used in the manufacture of Versameb’s VMB-100 for first-in-human clinical study
Based on prior manufacturing agreement that encompasses usage of Touchlight’s doggybone DNA (dbDNA™) to manufacture clinical supply of VMB-100 for Phase 2a trial to treat stress urinary incontinence (SUI). Hampton, UK – 21 November 2023 – Touchlight, a CDMO enabling the development of genetic medicines with its enzymatic doggybone DNA (dbDNA) technology, today announced that the Company … Continued
24 May 2023
Touchlight completes expansion, creating one of the world’s largest DNA manufacturing facilities in London, UK
Facility will have capacity that exceeds today’s global plasmid DNA demand and can enable commercialisation of genetic medicines. Transformation of Grade II-listed Victorian waterworks on the River Thames in Hampton, London. Supplying many of the top biopharmaceutical companies in the world to dramatically enhance their ability to develop genetic medicines. Expansion follows recent acceptance of … Continued